Author

J. A. Kulkarni

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:imaging· 1 Approach:microscopy & imaging analysis· 1

Frequent Co-Authors

R. M. Schiffelers· 2 shared R. Van der Meel· 2 shared A. B. Houtsmuller· 1 shared D. Duijvesz· 1 shared G. Jenster· 1 shared J. A. Slotman· 1 shared J. Zaifman· 1 shared M. A. Ciufolini· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

R. M. Schiffelers

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

EVQuant; high-throughput quantification and characterization of extracellular vesicle (sub)populations

T. A. Hartjes, J. A. Slotman, M. S. Vredenbregt-van den Berg, N. Dits, R. Van der Meel, D. Duijvesz, J. A. Kulkarni, P. J. French, W. A. van Cappellen, R. M. Schiffelers, A. B. Houtsmuller, G. Jenster, M. E. van Royen

EVQuant is a high-throughput microscopy-based assay that identifies, quantifies, and characterizes extracellular vesicle subpopulations in biofluids without extensive isolation.

bioRxiv · Oct 21, 2020 · PreprintBioengineering

Modular lipid nanoparticle platform technology for siRNA and lipophilic prodrug delivery

R. van der Meel, S. Chen, J. Zaifman, J. A. Kulkarni, X. R. S. Zhang, Y. K. Tam, M. B. Bally, R. M. Schiffelers, M. A. Ciufolini, P. R. Cullis, Y. Y. C. Tam

This paper demonstrates a modular lipid nanoparticle platform for co-delivering siRNA and lipophilic prodrugs to achieve additive anti-cancer effects in vitro.

bioRxiv · Jan 16, 2020Bioengineering